Monday 30 December 2024
Internal Reference Number: FOI_7303
Date Request Received: 12/07/2023 00:00:00
Date Request Replied To: 03/08/2023 00:00:00
This response was sent via: By Email
Request Summary: Lung cancer
Request Category: Private Individuals
| Question Number 1: In the past 3 months, how many early-stage (non-metastatic or Stages 1-3) Non-small cell lung cancer patients received the following treatments: Atezolizumab Durvalumab Nivolumab Pembrolizumab Chemotherapy (Platinum, Taxane, Vinorelbine, Gemcitabine, Pemetrexed) only Radiotherapy only Chemotherapy + radiotherapy | |
| Answer To Question 1: Atezolizumab <5 Durvalumab <5 Nivolumab <5 Pembrolizumab 0 Chemotherapy (Platinum, Taxane, Vinorelbine, Gemcitabine, Pemetrexed) only 0 Radiotherapy only - we do not do radiotherapy at this Trust so unable to respond to this and the category below Chemotherapy + radiotherapy | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
